Updates in Management of Complicated Urinary Tract Infections: A Focus on Multidrug-Resistant Organisms

American Journal of Therapeutics

Volumn 25, Issue 1, 2018, Pages e53-e66

  Ma, Adrienne H ^a   Hughes, Gregory J ^b  

^a Medstar Montgomery Medical Center   (United States)

^b ST JOHN'S UNIVERSITY   (United States)

Author keywords

antimicrobial stewardship; multidrug resistant organisms; pharmacology; urinary tract infections

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; CEFTOLOZANE PLUS TAZOBACTAM; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DAPTOMYCIN; FOSFOMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MEROPENEM PLUS VABORBACTAM; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; PLAZOMICIN; QUINOLONE DERIVATIVE; TIGECYCLINE; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL STEWARDSHIP; ARTICLE; CATHETER INFECTION; CITROBACTER; ENTEROBACTER; ESCHERICHIA COLI; HUMAN; KLEBSIELLA PNEUMONIAE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SERRATIA; STAPHYLOCOCCUS; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 85044066688     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0000000000000683     Document Type: Article

References (93)

1. Pfuntner A, Wier LM, Stocks C. Most Frequent Conditions in U.S. Hospitals, Agency for Healthcare Research and Quality; 2010. Available at: https://www.hcup-us.ahrq.gov/reports/statbriefs/sb148.pdf. Accessed January 28, 2017.
2. Hughes GJ, Beizer JL. Appropriate prescribing. In: Ham RJ, Sloane PG, Warshaw GA, et al, eds. Ham's Primary Care Geriatrics: A Case-Based Approach. 6th ed. Philadelphia, PA: Elsevier; 2014:67-76.
3. Coyle EA, Prince RA. Chapter 94. Urinary tract infections and prostatitis. In: DiPiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: A Pathophysiologic Approach. 9th ed. New York, NY: McGraw-Hill; 2014.
4. Nicolle LE. Asymptomatic bacteriuria: when to screen and when to treat. Infect Dis Clin North Am. 2003;17: 367-394.
5. Nicolle LE, Bradley S, Colgan R, et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005;40:643-654.
6. Cai T, Nesi G, Mazzoli S, et al. Asymptomatic bacteriuria treatment is associated with a higher prevalence of antibiotic resistant strains in women with urinary tract infections. Clin Infect Dis. 2016;61:1655-1661.
7. Marques LP, Flores JT, Barros O, et al. Epidemiological and clinical aspects of urinary tract infection in community-dwelling elderly women. Braz J Infect Dis. 2012;16:436-441.
8. Foxman B, Chi JW. Health behavior and urinary tract infection in college-aged women. J Clin Epidemiol. 1990; 43:329-337.
9. Nicolle LE. Catheter-related urinary tract infection. Drugs Aging. 2005;22:627-639.
10. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infections in adults: 2009 International clinical practice guidelines from the infectious diseases society of America. Clin Infect Dis. 2010;50: 625-663.
11. Nicolle LE. Urinary tract infections in the older adult. Clin Geriatr Med. 2016;32:523-538.
12. Albert X, Huertas I, Pereiró II, et al. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004:CD001209.
13. Gupta K, Hooton TM, Roberts PL, et al. Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women. Ann Intern Med. 2001;135:9-16.
14. Lavigne JP, Bourg G, Combescure C, et al. In-vitro and in-vivo evidence of dose-dependent decrease of uropathogenic Escherichia coli virulence after consumption of commercial Vaccinium macrocarpon (cranberry) capsules. Clin Microbiol Infect. 2008;14:350-355.
15. Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2012;17:10.
16. Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database Syst Rev. 2015:CD008772.
17. U. S. Food and Drug Administration: Novel Drug Approvals for 2012-2017. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm Accessed January 31, 2017.
18. Shionogi Announces Positive Top-Line Results for Cefiderocol Pivotal cUTI Clinical Trial. Available at: http://www.prnewswire.com/news-releases/shionogi-announcespositive-top-line-results-for-cefiderocol-pivotal-cuti-clinicaltrial-300389912.html. Accessed May 30, 2017.
19. Ceftriaxone. Micromedex® Healthcare Series. Greenwood Village, CO: Thomson Micromedex. Available at: http://thomsonhc.com. Accessed May 30, 2017.
20. Nitrofurantoin. Micromedex® Healthcare Series. Greenwood Village, CO: Thomson Micromedex. Available at: http://thomsonhc.com. Accessed May 30, 2017.
21. Sulfamethoxazole/Trimethoprim. Micromedex® Healthcare Series. Greenwood Village, CO: Thomson Micromedex. Available at: http://thomsonhc.com. Accessed May 30, 2017.
22. Fosfomycin. Micromedex® Healthcare Series. Greenwood Village, CO: Thomson Micromedex. Available at: http://thomsonhc.com. Accessed May 30, 2017.
23. Ampicillin. Micromedex® Healthcare Series. Greenwood Village, CO: Thomson Micromedex. Available at: http://thomsonhc.com. Accessed May 30, 2017.
24. Gentamicin/Tobramycin. Micromedex® Healthcare Series. Greenwood Village, CO: Thomson Micromedex. Available at: http://thomsonhc.com. Accessed May 30, 2017.
25. Levofloxacin. Micromedex® Healthcare Series. Greenwood Village, CO: Thomson Micromedex. Available at: http://thomsonhc.com. Accessed May 30, 2017.
26. Sanchez GV, Baird AM, Karlowsky JA, et al. Nitrofurantoin retains antimicrobial activity against multidrug-resistant urinary Escherichia coli from US outpatients. J Antimicrob Chemother. 2014;69:3259-3262.
27. Percival KM, Valenti KM, Schmittling SE, et al. Impact of an antimicrobial stewardship intervention on urinary tract infection treatment in the ED. Am J Emerg Med. 2015;33:1129-1133.
28. U.S. Food & Drug Administration: FDA Drug Safety Communication: FDA Updates Warnings for Oral and Injectable Fluoroquinolone Antibiotics Due to Disabling Side Effects. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm511530.htm. Accessed January 10, 2017.
29. Bains A, Buna D, Hoag NA. A retrospective review assessing the efficacy and safety of nitrofurantoin in renal impairment. Can Pharm J. 2009;142:248-252.
30. Geerts FJ, Eppenga WL, Heerdink R, et al. Ineffectiveness and adverse events of nitrofurantoin in women with urinary tract infection and renal impairment in primary care. Eur J Clin Pharmacol. 2013;69:1701-1707.
31. Singh N, Gandhi S, McArthur E, et al. Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women. CMAJ. 2015;187:648-656.
32. Ingalsbe ML, Wojciechowski AL, Smith KA, et al. Effectiveness and safety of nitrofurantoin in outpatient male veterans. Ther Adv Urol. 2015;7:186-193.
33. Mospan GA, Wargo KA. 5-Day versus 10-day course of fluoroquinolones in outpatient males with a urinary tract infection (UTI). J Am Board Fam Med. 2016;29: 654-662.
34. Thaden JT, Pogue JM, Kaye KS. Role of newer and reemerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. Virulence. 2016;6:1-14.
35. Pallett A, Hand K. Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria. J Antimicrob Chemother. 2010;65 (suppl 3):iii25-iii33.
36. Heintz BH, Halilovic J, Christensen CL. Vancomycinresistant enterococcal urinary tract infections. Pharmacotherapy. 2010;30:1136-1149.
37. Guidelines for antimicrobial treatment of acute uncomplicated cystitis and pyelonephritis in women. Clin Infect Dis. 2011;52:e103-e120.
38. Badalato G, Kaufmann M: Adult UTI. American Urological Association Website. Available at: https://www.auanet.org/education/adult-uti.cfm. Accessed January 15, 2017.
39. Peterson J, Kaul S, Khashab M, et al. A double-blind, randomized comparison of levofloxacin 750 mg oncedaily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology. 2008;71:17-22.
40. Ciprofloxacin. Micromedex® Healthcare Series. Greenwood Village, CO: Thomson Micromedex. Available at: http://thomsonhc.com. Accessed May 30, 2017.
41. Piperacillin/Tazobactam. Micromedex® Healthcare Series. Greenwood Village, CO: Thomson Micromedex. Available at: http://thomsonhc.com. Accessed May 30, 2017.
42. Aztreonam. Micromedex® Healthcare Series. Greenwood Village, CO: Thomson Micromedex. Available at: http://thomsonhc.com. Accessed May 30, 2017.
43. Imipenem/Cilastin. Micromedex® Healthcare Series. Greenwood Village, CO: Thomson Micromedex. Available at: http://thomsonhc.com. Accessed May 30, 2017.
44. Meropenem. Micromedex® Healthcare Series. Greenwood Village, CO: Thomson Micromedex. Available at: http://thomsonhc.com. Accessed May 30, 2017.
45. Daptomycin. Micromedex® Healthcare Series. Greenwood Village, CO: Thomson Micromedex. Available at: http://thomsonhc.com. Accessed May 30, 2017.
46. Linezolid. Micromedex® Healthcare Series. Greenwood Village, CO: Thomson Micromedex. Available at: http://thomsonhc.com. Accessed May 30, 2017.
47. Pham PA, Auwaerter PG. Tigecycline. Available at: https://www.unboundmedicine.com/ucentral/view/Johns-Hopkins-ABX-Guide/540549/all/Tigecycline?q5Tigecycline&ti50. Accessed May 30, 2017.
48. Dzintars K, Pham PA. Gentamicin. Available at: https://www.unboundmedicine.com/ucentral/view/Johns-Hopkins-ABX-Guide/540245/all/Gentamicin?q5Gentamicin&ti50. Accessed May 30, 2017.
49. Pham PA, Bartlett JG. Colistimethate (Colistin). Available at: https://www.unboundmedicine.com/ucentral/view/Johns-Hopkins-ABX-Guide/540140/all/Colistimethate-colistin-?q5Colistin&ti50#2/. Accessed May 30, 2017.
50. Nation Rl, Velkov TY, Li J, et al. Peas in a pod, or chalk and cheese? Clin Infect Dis. 2014;59:88-94.
51. Reffert JL, Smith WJ. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Pharmacotherapy. 2014;34:845-857.
52. Veve MP, Wagner JL, Kenney RM, et al. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum b-lactamase urinary tract infections. Int J Antimicrob Agents. 2016;48:56-60.
53. Morrill H, Pogue JM, Kaye KS, et al. Treatment options for carbapenem-resistant Enterobacteriaceae infections. Open Forum Infect Dis. 2015;2:ofv050.
54. Lee GC, Burgess DS. Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports. Ann Clin Microbiol Antimicrob. 2012;11:32.
55. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCse): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 2010;65:1119-1125.
56. Saint S, Greene T, Krein S, et al. A program to prevent catheter-associated urinary tract infection in acute care. N Engl J Med. 2016;374:2111-2119.
57. Pickard R, Lam T, MacLennan G, et al. Antimicrobial catheters for reduction of symptomatic urinary tract infection in adults requiring short-term catheterisation in hospital: a multicentre randomised controlled trial. Lancet. 2012;380:1927-1935.
58. Chenoweth CE, Gould CV, Saint S. Diagnosis, management, and prevention of catheter associated urinary tract infections. Infec Dis Clin N Am. 2014;28:105-119.
59. Nicolle LE. Catheter associated urinary tract infections. Antimicrob Resist Infect Control. 2014;3:23.
60. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62:e1-e50.
61. U.S. Food and Drug Administration: FDA Approves New Antibacterial Drug Zerbaxa. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427534.htm. Accessed February 2, 2017.
62. U.S. Food and Drug Administration: FDA Approves New Antibacterial Drug Avycaz. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435629.htm. Accessed February 2, 2017.
63. Cluck D, Lewis P, Stayer B, et al. Ceftolozane-tazobactam: a new-generation cephalosporin. Am J Health Syst Pharm. 2015;72:2135-2146.
64. Zerbaxa (R) [package insert]. Whitehouse station, NJ: Merck & Co, Inc; 2015.
65. Murano K, Ymanaka T, Toda A, et al. Structural requirements for the stability of novel cephalosporins to AmpC beta-lactamase based on 3D-structure. Bioorg Med Chem. 2008;18:2261-2275.
66. Moya B, Zamorano L, Juan C, et al. Activity of a new cephalosporin, CXA-101 (FR264205) against B-lactamresistant Pseudomonas Aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicr Agents Chemother. 2010; 54:1213-1217.
67. Golan Y. Empiric therapy for hospital-acquired, Gramnegative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options. BMC Infect Dis. 2015;15:313.
68. Wagenlehner FM, Umeh O, Steenbergen J, et al. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial. Lancet. 2015;385:1949-1956.
69. Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/-tazobactam plus metronidazole for complicated intraabdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial. Clin Infect Dis. 2015;60:1462-1471.
70. Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008). Available at: https://clinicaltrials.gov/ct2/show/NCT02070757. Accessed January 14, 2017.
71. Determine the PK and Safety and Tolerability of ATM-AVI for the Treatment of cIAIs in Hospitalized Adults. Available at: https://clinicaltrials.gov/ct2/show/NCT02655419?term5Aztreonam+Avibactam&rank52. Accessed January 14, 2017.
72. Singh R, Kim A, Tanudra MA, et al. Pharmacokinetics/pharmacodynamics of a b-lactam and b-lactamase inhibitor combination: a novel approach for aztreonam/avibactam. J Antimicrob Chemother. 2015;70: 2618-2626.
73. Zasowski EJ, Rybak JM, Rybak MJ. The β-Lactams strike back: ceftazidime-avibactam. Pharmacotherapy. 2015;35: 755-770.
74. Lahiri SD, Johnstone MR, Ross PL, et al. Avibactam and class C b-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance. Antimicrob Agents Chemother. 2014;58: 5704-5713.
75. Positive Phase III Results Demonstrate Efficacy of Antibiotic Medicine AVYCAZ™ (Ceftazidime-Avibactam) in Complicated Urinary Tract Infections. Available at: http://www.allergan.com/news/news/thomson-reuters/positive-phaseiii-results-demonstrate-efficacy-of. Accessed January 14, 2017.
76. Avycaz (R) [package insert]. Verona, Italy: Glaxo Smith Kline; 2017.
77. Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patient with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections: a randomised, pathogen-directed, phase 3 study. Lancet. 2016;16: 661-673.
78. Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intraabdominal infection. Clin Infect Dis. 2016;62:1380-1389.
79. The Medicines Company. Carbavance (Meropenem-Vaborbactam). Available at: http://www.themedicinescompany.com/investors/news/medicines-company-announcespositive-top-line-results-phase-3-tango-1-clinical-trial. Accessed January 17, 2017.
80. Safety and Efficacy of ZTI-01 (IV Fosfomycin) Vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections (ZEUS). Available at: https://clinicaltrials.gov/ct2/show/NCT02753946. Accessed January 14, 2017.
81. Fomicyt 40 mg/ml Powder for Solution for Infusion. Available at: https://www.medicines.org.uk/emc/medicine/28971/. Accessed February 4, 2017.
82. Garau: other antimicrobials of interest in the era of extended-spectrum b-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect. 2008;14: 198-202.
83. Cho YH, Jung SI, Chung HS, et al. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin. Int Urol Nephrol. 2015;47:1059-1066.
84. Falagas ME, Kastoris AC, Kapaskelis AM, et al. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010;10:43-50.
85. Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014) (RESTORE-IMI 2). Available at: https://www.clinicaltrials.gov/ct2/show/NCT02493764?term5relebactam&rank52. Accessed January 17, 2017.
86. Efficacy and Safety of Imipenem + Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium + Imipenem + Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013) (RESTORE-IMI 1). Available at: https://www.clinicaltrials.gov/ct2/show/NCT02452047?term5relebactam&rank51. Accessed January 17, 2017.
87. Toussaint KA, Gallagher JC. b-lactam/b-lactamase inhibitor combinations: from then to now. Ann Pharmacother. 2015;49:86-98.
88. Tetraphase Announces top 5 line Results From IGNITE2 Phase 3 Clinical Trial of Eravacycline in CUTI. Available at: http://ir.tphase.com/releasedetail.cfm?releaseid5930613. Accessed January 17, 2017.
89. Solomkin J, Evans D, Slepavicius A, et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg. 2017;152:224-232.
90. Aggen JB, Armstrong ES, Goldblum AA, et al. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother. 2010;54:4636-4642.
91. Achaogen Completes Patient Enrollment in Phase 3 EPIC Clinical Trial of Plazomicin. Available at: http://investors.achaogen.com/releasedetail.cfm?releaseid5987442. Accessed January 17, 2017.
92. Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-Resistant Gram-Negative Pathogens (CREDIBLE-CR). Available at: https://clinicaltrials.gov/ct2/show/NCT02714595. Accessed January 17, 2017.
93. Bartoletti R, Cai T, Perletti G, et al. Finafloxacin for the treatment of urinary tract infections. Expert Opin Investig Drugs. 2015;24:957-963.